Remission in Every Patient

Promising clinical response for rectal cancer patients. This weekend, Green Bay Oncology providers attended ASCO in Chicago where the results of a phase II trial was discussed involving patients with mismatch repair deficient locally advanced rectal cancer. These patients received treatment with PD-1 blockade, dostarlimab, and had a complete clinical response. This is exciting news […]